TABLE 2.
Frequency of HHV-6 DNA in the CSF of immunocompetent patients with high-level viral DNA in serum and/or whole blooda
| Patient no. (sex) | Age at onset of illness | High-levelb HHV-6 DNA
|
CSF
|
Clinical details | |||
|---|---|---|---|---|---|---|---|
| Presence in serum (variant) | Presence in whole blood (variant) | No. of samples testedc (no. of days between 1st and last samples) | No. of days after onset of illness that sample was taken | Presence of HHV-6 DNA (variant, log10 HHV-6 DNA copies/ml) | |||
| HL1 (M)d | 0 mo | + (B) | NT | 3 (186) | 5 | + (B, NT) | Cerebral abnormalities at birth, suspected sepsis/encephalitise |
| HL2 (F)f | 0 mo | +g (B) | +g (B) | 6 (174) | 5 | + (NT, 4.1) | Neonatal convulsions |
| HL3 (F)f | 0 mo | NT | +g (Bh) | 2 (232) | 3 | + (NT, 4.6) | Tachypneic, meconium aspiration |
| HL4 (M) | 0 mo | + (B) | NT | 1 (0) | 0 | + (NT, NT) | Neonatal convulsions, intractable epilepsye |
| HL5 (F) | 0 mo | +g (B) | +g (B) | 2 (0) | 21 | +g (B, 3.7) | Neonatal convulsions |
| HL6 (F)d | 0 mo | + (A) | NT | 2 (306) | 107 | + (NT, NT) | Intrauterine growth retardation, afebrile convulsions, developmental delay |
| 371 | + (A, 4.0) | ||||||
| HL7 (NK) | 4 mo | + (B) | NT | 1 (0) | 0i | + (B, 4.6) | Bulging fontanel, pyrexia, suspected meningococcal meningitis |
| HL8 (M)d | 4 mo | + (A) | NT | 6 (184) | 0 | + (NT, NT) | HSV-1 encephalitis |
| HL9 (M) | 10 mo | + (B) | NT | 1 (0) | 122 | + (B, 3.3) | Fever, convulsions |
| HL10 (F) | 11 mo | + (B) | NT | 1 (0) | 0 | + (B, 2.6) | Fever, convulsions |
| HL11 (M) | 1 yr, 1 mo | + (B) | NT | 1 (0) | 2 | − | Fever, rash, and convulsions |
| HL12 (NK) | 1 yr, 1 mo | + (B) | NT | 1 (0) | 0i | + (B, 2.9) | Pyrexia, rash |
| HL13 (F) | 1 yr, 3 mo | + (B) | NT | 1 (0) | 0i | + (NT, 5.2) | Encephalitis |
| HL14 (M)d | 1 yr, 11 mo | + (B) | NT | 10 (452) | 1 | + (B, 5.6) | Acute demyelinating encephalitis |
| 16 | + (B, 3.0) | ||||||
| HL15 (F)d | 2 yr, 9 mo | + (A) | NT | 3 (9) | 180 | + (A, NT) | Chronic/subacute encephalitis |
| 202 | + (NT, NT) | ||||||
| HL16 (M)d | 4 yr | + (B) | NT | 2 (15) | 0i | + (B, 4.6) | Fever, convulsions |
| HL17 (M) | 4 yr | + (B) | NT | 1 (0) | 0i | + (B, 2.6) | Convulsions, encephalopathy |
| HL18 (F)d | 12 yr | + (A) | NT | 5 (553) | 0 | + (A, NT) | Encephalitis |
| HL19 (M)d,f | 23 yr | +g (B) | +g (NT0) | 6 (1,701) | 0 | + (B, NT) | Epstein-Barr virus encephalitis |
| 25 | + (B, 3.6) | ||||||
| HL20 (F) | 52 yr | + (B) | NT | 1 (0) | 0i | − | HSV-1 encephalitis |
| 18 | + (B, 3.7) | ||||||
| HL21 (F)f | 58 yr | +g (B) | +g (B)h | 2 (3) | 1 | +g (B, 5.5) | Meningitis, Parkinson's disease |
a
Abbreviations: NT, not tested; M, male; F, female; NK, not known.
b
High level, >3.5 log10 copies/ml in serum; >6.0 log10 copies/ml in whole blood.
c
High level in every sample tested.
d
See reference 47 for more detail.
e
Mother has high-level serum HHV-6 DNA.
f
HHV-6 chromosomal integration identified by fluorescent in situ hybridization and ≥1 HHV-6 DNA copy/hair follicle cell (46).
g
≥1 HHV-6 DNA copy/cell or lysed cell (46).
h
Detected in lymphoblastoid cell line derived from this patient's blood.
i
Onset date unknown, so day of first sample defined as 0.